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Abstract
Background:  Gastrointestinal stromal tumours (GIST) usually present with non-specific
gastrointestinal symptoms such as abdominal mass, pain, anorexia and bowel obstruction.
Methods: We report a case of a 42 year old male who presented with a solitary intracranial space
occupying lesion which was established as a metastasis from a mesenteric tumour.
Results: The patient was initially treated as a metastatic sarcoma, but a lack of response to
chemotherapy prompted testing for CD117 which returned positive. A diagnosis of mesenteric
GIST presenting as solitary brain metastasis was made, and the patient was treated with imatinib.
Conclusion: We recommend that all sarcomas with either an intraabdominal or unknown origin
be routinely tested for CD117 to rule out GIST.
Background
Gastrointestinal stromal tumours (GIST) are thought to
arise from the interstitial cells of Cajal, the intestinal pace-
maker cells [1]. GIST commonly arises from the stomach
and small intestine and usually presents with non-specific
abdominal symptoms [2]. GIST mostly metastasizes
within the abdomen [3]. To our knowledge, GIST present-
ing with brain metastasis has not been reported in the lit-
erature. We report a case of a 42 year old male who
presented with a solitary intracranial space occupying
lesion which was subsequently established to be a metas-
tasis from a mesenteric GIST.
Case presentation
A 42-year-old male presented in January 2004 complain-
ing of headache and left-sided weakness of eight months
duration and vomiting of four months duration. There
was no history of trauma, seizures or loss of conscious-
ness. Computed Tomography (CT) scan of the brain (Fig-
ure 1) showed a 3.5 cm sized ring-enhancing mass in the
right parietal lobe with significant perilesional oedema.
Magnetic resonance imaging (MRI) of the head showed
the mass to be isointense on T1 and hypointense on T2
weighted images. The patient underwent right parietal
craniotomy with gross total excision of the tumour. His-
topathology of the operative specimen showed features of
undifferentiated sarcoma with areas of necrosis (Figure 2).
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The pathological differential diagnoses given were meta-
static sarcoma and primary intracranial sarcoma. Radio-
graphic skeletal survey, chest x-ray and ultrasonogram of
the abdomen were normal at this time. The patient was
treated with postoperative cranial radiotherapy to a dose
of 60 Gray with concomitant chemotherapy with carbopl-
atin at a dose of 150 mg weekly.
The patient remained asymptomatic till June 2004 when
he complained of abdominal fullness and pain. CT of the
abdomen showed a large mesenteric mass measuring 8 ×
6 cm in size. An ultrasound guided tru-cut biopsy from the
mesenteric mass revealed a malignant spindle cell tumour
with morphology similar to that of the brain tumour. The
mitotic index of the abdominal tumour was 10 per 50
HPF (high power fields). Immunohistochemistry was
positive for CD34, vimentin; and negative for GFAP (glial
fibrillary acidic protein) and SMA (smooth muscle actin).
Thereafter the patient was treated with six cycles of combi-
nation chemotherapy with ifosfamide 1.8 gm/m2 i.v. D1-
4 with mesna uroprotection and epirubicin 60 mg/m2 i.v.
in two divided doses, as 3-weekly cycles until November
2004. However, there was no apparent clinical response to chemotherapy, and abdomen CT (Figure 3) done at this
time showed a 10 × 8 cm sized heterogeneously enhanc-
ing mesenteric mass.
Given the failed response to chemotherapy, the pathology
specimen was retested for CD117/c-kit which turned out
to be positive. Thus, the patient was diagnosed as a pri-
mary mesenteric gastrointestinal stromal tumour present-
ing as solitary brain metastasis. The patient was then
treated with imatinib mesylate 600 mg oral daily. CT scan
Contrast enhanced CT (CECT) scan of the abdomen done in  November 2004 after 6 cycles of ifosfamide and epirubicin  combination chemotherapy showing a 10 × 8 cm sized heter- ogeneously enhancing mesenteric mass Figure 3
Contrast enhanced CT (CECT) scan of the abdomen done in 
November 2004 after 6 cycles of ifosfamide and epirubicin 
combination chemotherapy showing a 10 × 8 cm sized heter-
ogeneously enhancing mesenteric mass.
CT scan of the brain showing a 3.5 cm sized ring-enhancing  mass (arrow) in the right parietal lobe with significant mass  effect and compression of the right lateral ventricle Figure 1
CT scan of the brain showing a 3.5 cm sized ring-enhancing 
mass (arrow) in the right parietal lobe with significant mass 
effect and compression of the right lateral ventricle. There is 
significant peri-lesional oedema.
Section from operative specimen from right parietal lobe  lesion shows features of undifferentiated sarcoma with areas  of necrosis Figure 2
Section from operative specimen from right parietal lobe 
lesion shows features of undifferentiated sarcoma with areas 
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of the chest and abdomen after three months of therapy
showed a good response, evidenced by a cystic conversion
of tumour mass with no visible areas of enhancement
(Figure 4). The patient continued to remain on imatinib
therapy. However, after the initial response, CT scan of
abdomen done after another three months showed a focal
nodular area of enhancement (arrow) within the
mesenteric mass, suggestive of disease progression. (Fig-
ure 5) The patient subsequently developed cachexia and
died four months later.
Discussion
Gastrointestinal stromal tumours (GIST) are thought to
arise from the interstitial cells of Cajal, the intestinal pace-
maker cells [1]. GIST most commonly arises from the
stomach (60–70%) and small intestine (20–30%) with
less than 10% arising from the rest of gastrointestinal tract
(oesophagus, colon, rectum) or extraintestinal sites
(omentum, mesentery, retroperitoneum) [2-4].
The clinical presentation of patients with GIST can vary
depending on the tumour location, size and aggressive-
ness. Typically, patients present with non-specific gas-
trointestinal symptoms such as abdominal mass, pain,
vomiting, anorexia and bowel obstruction. Rarely,
patients may present with acute haemorrhage into perito-
neal cavity from tumour rupture or cutaneous metastases
[5,6].
GIST mostly metastasizes within the abdomen. In one
series of 83 patients [7], the common sites of metastases
were to the liver (46%) and peritoneum (41%). Other
sites of metastases reported in this series include the retro-
peritoneum, lung, bone and abdominal scar. Involvement
of the central nervous system (CNS) by metastatic GIST is
extremely rare. A review of the literature reveals only three
reports of CNS involvement by GIST. In all cases, patients
had known metastatic disease elsewhere prior to the
development of CNS metastases. In one case [8], a 60-
year-old male with diagnosed metastatic GIST developed
sudden unilateral blindness that was found to be caused
by metastatic involvement of the cavernous sinus. In the
second case [9], a 47-year-old male who was being treated
with imatinib for metastatic GIST developed multiple cer-
ebral relapses even while systemic disease appeared to be
controlled. In the third case [10], a 75-year-old male with
multiple liver and peritoneal metastases developed a sin-
gle intracranial lesion. In the third patient, all lesions
including the intracranial lesion showed a good response
to imatinib therapy.
In the present case, the patient had an unusual presenta-
tion as an intracranial metastasis. The patient was initially
treated as a metastatic sarcoma from unknown primary
due to the absence of extracranial disease on radiological
workup. Even after the detection of the mesenteric pri-
mary, the patient was initially treated as a mesenteric sar-
coma as histopathology showed a sarcoma which was
positive for CD34 and vimentin antigen. The possibility
of GIST was suspected only after the patient failed to
respond to ifosfamide and epirubicin combination chem-
otherapy. As the immunohistochemisty returned positive
for CD117 at this stage, the patient was treated with imat-
inib [11,12]. A good initial treatment response was noted
with imatinib, with a reduction in tumour size and the
development of cystic changes in the tumour mass. How-
CECT of the abdomen done three months after that in Fig- ure 4 showing a focal nodular area of enhancement (arrow)  within the mesenteric mass, which is suggestive of disease  progression Figure 5
CECT of the abdomen done three months after that in Fig-
ure 4 showing a focal nodular area of enhancement (arrow) 
within the mesenteric mass, which is suggestive of disease 
progression. The patient died four months later.
CECT of the abdomen done after three months of imatinib  therapy showing a good response, evidenced by a cystic con- version of the mesenteric mass with no enhancing areas  within Figure 4
CECT of the abdomen done after three months of imatinib 
therapy showing a good response, evidenced by a cystic con-
version of the mesenteric mass with no enhancing areas 
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ever, the patient subsequently developed progressive dis-
ease and died.
Conclusion
The present report describes a unique presentation of
GIST as intracranial metastasis. To the best of our knowl-
edge, this is the first report of its kind in the literature. The
true nature of disease remained obscure for a considerable
duration; this delay could be attributed, in part to the
atypical presentation and to the lack of routine testing for
CD117. We recommend that all cases of sarcomas with an
intraabdominal origin or unknown origin be routinely
tested for CD117 to detect GIST as these tumours usually
respond to imatinib.
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